Olema Pharmaceuticals Q1 net loss widens on higher R&D costs

Olema Pharmaceuticals

12/05/2026 12:07

Overview

US biopharmaceutical firm's Q1 net loss widened yr/yr due to higher R&D and G&A expenses

Company ended Q1 with $505.3 mln in cash, cash equivalents, and marketable securities

Increased expenses driven by late-stage palazestrant trials and early-stage OP-3136 studies

Outlook

Olema expects top-line data from Phase 3 OPERA-01 trial in fall 2026

Company anticipates first commercial launch in 2027, pending clinical results

Company to present initial clinical data from OP-3136 Phase 1 study at ASCO in 2026

Result Drivers

CLINICAL DEVELOPMENT SPENDING - Higher R&D expenses driven by increased spending on late-stage palazestrant trials and advancement of OP-3136 studies

PERSONNEL COSTS - Increased personnel-related costs, including higher non-cash stock-based compensation, contributed to higher R&D and G&A expenses

Company press release: ID:nGNXbblD0H

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Net Income
-$53.09 mln
Q1 Income From Operations
-$57.99 mln
Q1 Operating Expenses
$57.99 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 12 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Olema Pharmaceuticals Inc is $40.00, about 169.2% above its May 11 closing price of $14.86

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)